

Ticker:	MLSS
Exchange:	OTCBB/OTCQB
Share price (as of 2/3/14):	\$1.40
Common shares outstanding:.....	17.6 M
Market capitalization:	24.7 M
9 months revenue:.....	\$7.2 M
9 months net income:.....	\$443,227
Total Shareholders' Equity (9/30/13):	\$3.8 M
Fiscal year-end:	December 31
Security Ownership of Mngmt:	23.2%

About Milestone Scientific

Milestone Scientific Inc. is a leading medical research and development company that designs and patents innovative injection technology. Milestone has developed epidural and intra-articular drug delivery systems based on patented, painless, computer-controlled injection and drug delivery instruments with related disposables. In dentistry, it is the first major breakthrough in injection technology since the invention of the hypodermic syringe. By using pressure sensing technology, Milestone enables healthcare practitioners to administer pain-free injections by controlling the flow rate of the fluid being injected. There are extensive opportunities for the company to broaden its market to include self-administered applications such as diabetes, multiple sclerosis and rheumatoid arthritis, cosmetic surgery, ophthalmic surgery and neurosurgical injections. The company has 24 issued patents and has won a number of awards over the past three years in the dental community, where Milestone currently derives its revenue.

Investment Highlights

- ✓ Recent partnership with Tri-anim provides expansive distribution for the epidural instrument in the USA
- ✓ Milestone Medical subsidiary recently listed on the Warsaw Stock Exchange and raised capital at a \$33 million post money valuation
- ✓ Conventional needle syringes present significant challenges for patients, doctors and the medical industry – including safety, cost, and malpractice insurance
- ✓ Over 24 patents surrounding injection/drug delivery system
- ✓ Patented and FDA approved painless injection/drug delivery system
- ✓ Opportunity to expand into new drug delivery applications
- ✓ Disposable handpieces create high-margin recurring-revenue model

Company Profile

- Proprietary computer-controlled injection technologies targeting the medical and dental markets
- First major breakthrough in injection technology since invention of hypodermic syringes
- Precision, painless injections for all dental treatments
 - Root canals, crowns, fillings, cleanings, etc.
 - Over 50 million injections administered to date
- Award-winning products
- Global distribution network
 - North and South America, Asia, Africa and Europe
 - IP portfolio consists of 24 issued patents
- Medical applications
 - Epidural Application
 - Osteoarthritis Application

Core CompuFlo®/DPS® Technology

- Regulates and controls flow rate of fluid
- Dynamic Pressure Sensing® capability provides visual and audible in-tissue pressure feedback in real time
 - Ability to identify tissue types and inject drugs in the precise location
 - Minimizes tissue damage and eliminates the pain of the injection because the flow rate and pressure of the injection are controlled
- Disposable injection handpiece allows precise tactile control during the injection
- Demonstrated success in dentistry, dermatology, rhinoplasty, podiatry and other uses

Medical Applications

- Unique ability to identify the tissue in which the needle tip is imbedded
 - Management believes our products will improve safety, reduce costs including malpractice and broaden the market
- Over 700 potential injection applications according to an independent analysis
 - Clinical evidence demonstrating benefits in epidurals, intra-articular injections, colorectal surgery, podiatry, dermatology, nasal/sinus surgery, hair transplant and cosmetic surgery
 - Other applications include: neurosurgical injections/aspirations, ophthalmic surgery, cosmetic surgery, botox, dermatology, etc.
- New products subject to 510(k) submission, reducing cost and time to market



Milestone Medical

- In November Milestone Medical raised \$3M from European investors at a post money valuation of \$33M and listed on the Warsaw Stock Exchange under the ticker MMD
- The two products developed are epidural and intra-articular drug delivery instruments utilizing DPS® technology
- Milestone provides exclusive worldwide royalty-free license for use of its patents as they relate to these 2 instruments




Tri-anim Health Services Partnership

- Three-year agreement announced in July 2013; begins after FDA marketing clearance
- Tri-anim to be distributor of Milestone's epidural injection technology for childbirth and other pain management needs in the pain management/hospital sector
 - Nation's largest provider of specialty sales and distribution solutions for healthcare, and largest distributor to birthing pain management centers
 - Tri-Anim is a division of Sarnova, which offers healthcare products to thousands of customers across the U.S.
 - Partnership gives Milestone's products national reach




Medical Market Overview: Epidural

- Epidural market is estimated over \$1 billion annually per year in the U.S. alone
 - 2.4 million women receive epidurals while in labor each year in the U.S.
 - More than 8.9 million epidurals administered for other purposes each year
- Doctors using conventional syringes identify the epidural space by relying on subjective perception
 - 1 in 30 women suffer complications with conventional standard of care – ranging from severe pain to wet tap to paraplegia and even death
 - Average cost per epidural malpractice settlement: \$362,000



Epidural Instrument

- In clinical studies, Milestone's epidural instrument reliably identified pressure characteristics of the different tissues, including the decrease in pressure in the epidural space
- Practitioners using Milestone's instrument correctly identified the epidural space with a success rate of 100%
- Milestone partnership with Tri-anim speeds distribution



Osteoarthritis

- Intra-articular market expected to reach \$7 billion by 2015
 - Osteoarthritis affects 33 million patients in U.S. alone
 - 21 million in U.S. receive intra-articular injections
- Conventional injections lack precision, as doctors often fail to locate the intra-articular space and/or use inappropriate volumes of drugs



The Wand® Computer Controlled Anesthesia System

- Allows dentists to administer injections accurately and painlessly into the periodontal ligament space, effectively anesthetizing a single tooth
- Anesthetizes the tooth within one or two minutes versus 8-18 minutes for a block injection
 - No pain or collateral anesthesia in the cheek, lips or tongue
- Capable of performing all injections done with a conventional syringe
- Over 50 million injections successfully delivered to date



Aseptico Partnership

- Formed strategic alliance with Aseptico
 - Aseptico will serve as the exclusive distributor The Wand computer controlled anesthesia system and related disposable items
 - Aseptico has served the dental market for over 38 years and markets their products to over 150,000 dentists across the U.S. and Canada
- Aseptico will take over responsibility for sales directly to individual dentists and small offices
 - Expected to significantly reduce sales and marketing expenses
 - Aseptico participates in over 70 dental shows annually
 - Will attend pediatric dental shows in the U.S. and Canada
 - Aseptico has committed to an active advertising initiative targeting major dental publications, as well as direct mailing campaigns

Financial Results

- Revenue for the nine months ended September 30, 2013 was \$7.2 million versus \$6.4 million for same period in 2012
 - Total domestic sales increased 20% to \$3.9 million
 - Achieved a 52.0% increase in domestic instrument sales
 - International sales increased to \$3.3 million versus \$3.1 million
- Gross profit increased 17.5% to \$5.0 million versus the same period in 2012
 - Gross margin increased 260 basis points to 69.0%
- Third consecutive quarter of profitability

For Additional Information

Investor Contact:
David K. Waldman/Natalya Rudman
Crescendo Communications, LLC
(212) 671-1020
mlss@crescendo-ir.com

The information contained herein was obtained from Milestone Scientific and other sources Crescendo Communications, LLC believes to be reliable. This does not constitute the solicitation of the purchase or sale of securities. Crescendo is employed by the Company as its investor relations firm. Except for the historical information contained herein, the matters discussed in this document are forward-looking statements, the accuracy of which are necessarily subject to risks and uncertainties. Certain of these risks and uncertainties will be described in greater detail in Milestone Scientific's filings with the Securities and Exchange Commission.